Hiraoka et al reported the Tumor Marker (TM) score for evaluating a patient with intermediate-stage hepatocellular carcinoma (HCC). The authors are from multiple institutions in Japan.
Patient selection: intermediate-stage hepatocellular carcinoma
Parameters:
(1) serum alpha fetoprotein (AFP) in ng/mL
(2) fucosylated AFP (AFP-L3) in percent
(3) des-gamma-carboxy prothrombin in mAU/mL
Parameter
Finding
Points
serum AFP
< 100 ng/mL
0
>= 100 ng/mL
1
fucosylated AFP-L3
< 10%
>= 10%
des-gamma-carboxy prothrombin
< 100 mAU/mL
>= 100 mAU/mL
total score =
= SUM(points for all of the parameter)
Interpretation:
• minimum score: 0
• maximum score: 3
Total Score
Hazard Ratio
Median Survival
1.0
4.8 years
1.6
3.8 years
2 or 3
2.2
3.2 years
To read more or access our algorithms and calculators, please log in or register.
Specialty: Hematology Oncology
